A phase 3 randomised study of enzalutamide plus leuprolide and enzalutamide monotherapy in high-risk non-metastatic hormone-sensitive prostate cancer with rising PSA after local therapy: EMBARK study design.
Stephen J FreedlandUgo De GiorgiMartin GleaveBrad RosbrookQi ShenJennifer SuggGabriel P HaasNeal D ShorePublished in: BMJ open (2021)
NCT02319837.